Many investors and researchers have been predicting a psychedelics boom, with MDMA being just the first of a number of psychedelics in the drug development pipeline.
On the cost of psilocybin, adult versus medical programs, and FDA developments. Based on “interviews with facilitators, service center owners, manufacturers, researchers and policymakers in Oregon.”
Jimmy Carberry on old marijuana myths, Olivetol, and the importance of cannabis consumer education
How a product like mushroom gummies can fall through the regulatory cracks
Not just marijuana naloxone, we’re using some of these softgels to refresh
Flower and gummy line from Coyote Cannabis are latest additions to Bay State Wu-Tang weedscape
Oh, you’re not a soda drinker? Well you are now.
Founder of Connecticut for Accessible Psychedelic Medicine tells TJM: “When people see that their own lives can improve, it builds a community [that] is willing to fight.”
New variant of perennial favorite edible has our mouths gushing and tongues twitching
“One of the biggest misconceptions I hear is that psychedelics are ‘white people stuff.’ This is far from the truth.”
